Hematopoietic stem cells have long been of interest for their possible therapeutic applications. Umbilical cord blood was identified as a third source of these stem cells after the discovery of bone marrow and peripheral blood. It has since been designated as a drug by the United States FDA (Food and Drug Administration), meaning it must meet strict federal regulations.
Stem cells are critical for both scientific discovery and for stem cell transplantation into sick patients as a therapeutic agent. However, stem cells are rarely assessed for quality, identity, and purity before their use. This is important when considering that effective therapies would likely need to be robust and reproducible on a large scale. At the same time, successful scientific experiments require consistent cell types and quantities.
To remove this obstacle, Leo Corps and affiliative companies offers both the largest selection of hematopoietic stem cell therapy assays on the market and also human cell lines. These products are applicable to different stages of the stem cell transplantation process, such as separating out high quality stem cells, as well as monitoring patients after the transplantation procedure.
It is our goal to set the bar as high as possible so that researchers receive the highest quality, and most effective products available.